Table 1.
Baseline characteristics of patients treated with immunotherapy monotherapy (mono-IT) and in combination with chemotherapy (chemo-IT).
| Characteristic | Mono-IT n=118 (100%) |
Chemo-IT n=58 (100%) |
|
|---|---|---|---|
| Median age (range), years | 64 (39–81) | 64 (46-76) | |
| Sex | Female | 48 (41) | 21 (36) |
| Male | 70 (59) | 37 (64) | |
| Smoking | Former or current | 104 (88) | 52 (90) |
| Never | 14 (12) | 6 (10) | |
| Histology | Squamous | 21 (18) | 15 (26) |
| Nonsquamous | 97 (82) | 43 (74) | |
| ECOG PS | 0-1 | 95 (80) | 53 (91) |
| ≥ 2 | 23 (20) | 5 (9) | |
| CNS metastasis | With | 16 (14) | 4 (7) |
| Without | 102 (86) | 54 (93) | |
| PD-L1 | ≥ 50% | 118 (100) | 5 (9) |
| 1-49% | 0 (0) | 31 (54) | |
| <1% | 0 (0) | 22 (38) | |
| KRAS | Mutated | 47 (40) | 21 (36) |
| Wildtype | 71 (60) | 37 (63) | |
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; ICI. immune checkpoint inhibitor; IQR, interquartile range; KRAS, Kirsten rat sarcoma oncogene; PD-L1, programmed death-ligand 1; PS, performance status.